January 4, 2024 10:47 AM ESTUpdated January 5, 07:43 AM
News Briefing

Rhythm li­cens­es obe­si­ty drug for $100M; Gala­pa­gos teams up with Brid­Gene; In­sil­i­co’s new deal

ENDPOINTS

Plus, news about Boehringer In­gel­heim, Mer­ck KGaA, Atai Life Sci­ences, Re­salis Ther­a­peu­tics, Portage Biotech, Sen­sei Bio­ther­a­peu­tics and ADC Ther­a­peu­tics:

Rhythm li­cens­es obe­si­ty drug for …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Trump names Johns Hop­kins re­searcher Mar­ty Makary to lead the FDA; al­so names CDC, Sur­geon Gen­er­al picks

FDA ap­proves Bridge­Bio's heart dis­ease drug, set­ting up com­pe­ti­tion with Pfiz­er, Al­ny­lam

Sur­round­ed by AI bio gi­ants, tiny start­up Nabla Bio makes de no­vo an­ti­bod­ies look more like drugs 

Drug or bi­o­log­ic? An Eli Lil­ly law­suit could im­pact weight loss drug com­pounders

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times